Coherus BioSciences (CHRS) and Junshi Biosciences Announce Publication of Positive Final Overall Survival Results of JUPITER-02 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
– Final overall survival analysis of the JUPITER-02 trial shows first-line treatment with LOQTORZI plus chemotherapy significantly prolongs survival in patients with recurrent or metastatic NPC.
China’s National Medical Products Administration has accepted a supplemental new drug application seeking the approval of toripalimab in combination with platinum-based chemotherapy for the first-line treatment of patients with extensive-stage small cell lung cancer.
China s NMPA Accepts sNDA for Frontline Toripalimab Plus Axitinib in Metastatic RCC onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.
The National Medical Products Administration has accepted the supplemental new drug application seeking the approval of toripalimab in combination with nab-paclitaxel in patients with untreated metastatic or recurrent triple-negative breast cancer and a PD-L1 combined positive score of at least 1.